{"id":"cbd-synthetic-form","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201467","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The synthetic CBD binds to cannabinoid receptors in the body, influencing various physiological processes. This interaction can lead to reduced inflammation, improved mood, and other therapeutic benefits.","oneSentence":"CBD, a synthetic form, interacts with the body's endocannabinoid system to produce therapeutic effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:43.446Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant epilepsy"},{"name":"Multiple sclerosis spasticity"}]},"trialDetails":[{"nctId":"NCT07148206","phase":"PHASE3","title":"Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT05832281","phase":"PHASE2","title":"Role of CBD in Improving Alexithymia","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2023-11-28","conditions":"Alexithymia, HIV","enrollment":5},{"nctId":"NCT04056442","phase":"PHASE2","title":"A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients","status":"COMPLETED","sponsor":"Stero Biotechs Ltd.","startDate":"2019-07-07","conditions":"Steroid Dependent Crohn's Disease","enrollment":15},{"nctId":"NCT06353828","phase":"PHASE2","title":"Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"CannaMore Biotechs","startDate":"2023-03-01","conditions":"Ulcerative Colitis","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CBD, synthetic form","genericName":"CBD, synthetic form","companyName":"CannaMore Biotechs","companyId":"cannamore-biotechs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A synthetic form of cannabidiol (CBD) is being studied as a potential treatment for various conditions, including Steroid Dependent Crohn's Disease, Ulcerative Colitis, Opioid Use Disorder, Alexithymia, and HIV. Clinical trials are evaluating the safety, tolerability, and efficacy of this synthetic CBD in comparison to a placebo.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}